Skip to main content
Equibles
ZVSA logo

ZVSA · ZyVersa Therapeutics, Inc.

Track ZVSA — free

Use ZVSA with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research ZVSA.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.19 -0.13 (-40.51%) At close · Jul 17
Rebalance outlook locked
Going-concern doubt — flagged May 13, 2026

Substantial doubt about the company's ability to continue as a going concern.

“These uncertainties raise substantial doubt about our ability to continue as a going concern for 12 months after the issuance date of our financial statements.”
View the 10-Q filed May 13, 2026
Market Cap
$833,880
Shares
8.10M
Volume · Jul 17 1.71M Avg daily vol (3M) 5.63M

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$0.19 Open$0.16 Day$0.16–0.25 52W close$0.19–4.35 Avg vol 30d8.5M Short int142K · 1.7% float · 7.0d Short vol28% Last earningsNov 14, 2024 DataFeb 2022–Jul 2025 Filing10-Q · May 13

Up next

Latest filing: 10-Q
filed May 13, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
−$24.49M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$302,660
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+160.6%
Year over year · more shares
Price change (1Y)
-95.7%
Trailing year
Short interest
—
Latest settlement
View all 115 metrics

Equibles Rating

blended score · not investment advice
Overall
Strong Sell
SellHoldBuy
Technical Sell Momentum Very Weak Sentiment Bearish Fundamentals Limited Quant / Vol Very High
Market backdrop VIX 15.5 · calm Equity put/call 0.59
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg −83%
below
Price vs 50-day avg −69%
below
RSI (14) 24
oversold
MACD trend Negative
52-week position 0%
near low
Volume (OBV) Bullish div.
accumulating
Momentum
relative strength
Very Weak
1-month return −71%
trailing
6-month return −88%
trailing
YTD return −83%
this year
Relative strength −91%
vs S&P · 6-mo
Sentiment
smart money
Bearish
Trend (MA cross) No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow Distributing
-86% holders QoQ · +1 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Flat
1.75% of float · ▬ 0.0% MoM · 7.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr low
1 holders — near 3-yr low, contrarian setup
Fundamentals
Limited
Not enough data for a confident read.
Quant / Vol
risk profile
Very High
Volatility 176%
annualized · 1-yr
Max drawdown −96%
past year
ATR 70.1%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Sell
4 · 2 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−83% Bearish
Price vs 50-day avg
−69% Bearish
RSI (14)
24 Neutral
MACD trend
Negative Bearish
52-week position
0% Bearish
Volume (OBV)
Bullish div. Bullish
Market signals — smart money & positioning
Bearish · 1 of 6
Trend (MA cross) No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow Distributing
-86% holders QoQ · +1 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Flat
1.75% of float · ▬ 0.0% MoM · 7.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr low
1 holders — near 3-yr low, contrarian setup
Price context
position in its 52-week range
Range low $0 Now $0 · 0% Range high $4
vs 200-day avg -83% vs 50-day avg -69%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
ZVSA
ZyVersa Therapeutics, Inc.
this stock
$833,880 — — — 1.7%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $133.37B +11.1% +46.2% 30.7 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
 $81.13B -5.9% +20.8% 19.5 2.5%
MRNA
Moderna, Inc.
 $79.40B +589.1% +4.3% — 8.2%
CSLLY
Csl Ltd
 $61.25B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
1
% held
0.0%
Net QoQ
-66.1K sh
Top holder
Guerra Advisors Inc
Held Float
View
Short & Settlement
Short Interest
Shares short
141.6K
Days to cover
7.0d
Change
0 sh
View
Short Volume
Short vol %
28%
As of
Aug 18, 2026
Short Total
View
Fails to Deliver
FTD shares
1
Value
$0
As of
Jul 31, 2026
View
Off-Exchange
Off-exchange %
64.1%
Week of
Jul 14, 2025
Off-exch Lit
View
Financials
Financials
Net income (FY)
$-25.0M
EPS diluted
$-4.18
View
Filings
SEC Filings
Latest
8-K
Filed
Jul 16, 2026
This year
5
View
Earnings & Events
Webcasts
Last webcast
Nov 14, 2024
View

Performance

5D 20D 120D MTD YTD
ZVSA -68.6% -71.1% -87.8% -72.7% -82.6%
SPY +0.4% +5.1% +3.0% +1.7% +7.2%
vs SPY -69.0% -76.2% -90.8% -74.3% -89.7%
Key facts CIK 1859007 CUSIP 98987D300 Visit website Investor relations